Mahller YY - Search Results

1

Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.

Maldonado AR, Klanke C, Jegga AG, Aronow BJ, Mahller YY, Cripe TP, Crombleholme TM. Maldonado AR, et al. Among authors: mahller yy. J Gene Med. 2010 Jul;12(7):613-23. doi: 10.1002/jgm.1479. J Gene Med. 2010. PMID: 20603890

2

Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses.

Currier MA, Adams LC, Mahller YY, Cripe TP. Currier MA, et al. Among authors: mahller yy. Cancer Gene Ther. 2005 Apr;12(4):407-16. doi: 10.1038/sj.cgt.7700799. Cancer Gene Ther. 2005. PMID: 15665822

3

Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.

Mahller YY, Rangwala F, Ratner N, Cripe TP. Mahller YY, et al. Pediatr Blood Cancer. 2006 Jun;46(7):745-54. doi: 10.1002/pbc.20565. Pediatr Blood Cancer. 2006. PMID: 16124003

4

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP. Mahller YY, et al. Mol Ther. 2007 Feb;15(2):279-86. doi: 10.1038/sj.mt.6300038. Mol Ther. 2007. PMID: 17235305 Free article.

5

Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP. Mahller YY, et al. Cancer Res. 2008 Feb 15;68(4):1170-9. doi: 10.1158/0008-5472.CAN-07-2734. Cancer Res. 2008. PMID: 18281493 Free PMC article.

6

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Currier MA, Gillespie RA, Sawtell NM, Mahller YY, Stroup G, Collins MH, Kambara H, Chiocca EA, Cripe TP. Currier MA, et al. Among authors: mahller yy. Mol Ther. 2008 May;16(5):879-85. doi: 10.1038/mt.2008.49. Epub 2008 Mar 25. Mol Ther. 2008. PMID: 18388918 Free PMC article.

7

Targeting cancer-initiating cells with oncolytic viruses.

Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PW. Cripe TP, et al. Among authors: mahller yy. Mol Ther. 2009 Oct;17(10):1677-82. doi: 10.1038/mt.2009.193. Epub 2009 Aug 11. Mol Ther. 2009. PMID: 19672244 Free PMC article. Review.

8

Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.

Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, Mehrian-Shai R. Mahller YY, et al. Cancer Gene Ther. 2008 Nov;15(11):733-41. doi: 10.1038/cgt.2008.40. Epub 2008 Jun 13. Cancer Gene Ther. 2008. PMID: 18551144 Free PMC article.

9

Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.

Parikh NS, Currier MA, Mahller YY, Adams LC, Di Pasquale B, Collins MH, Cripe TP. Parikh NS, et al. Among authors: mahller yy. Pediatr Blood Cancer. 2005 May;44(5):469-78. doi: 10.1002/pbc.20268. Pediatr Blood Cancer. 2005. PMID: 15570577

10

Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.

Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. Mahller YY, et al. PLoS One. 2009;4(1):e4235. doi: 10.1371/journal.pone.0004235. Epub 2009 Jan 21. PLoS One. 2009. PMID: 19156211 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page